Navigation Links
SIRO Clinpharm Announces Appointment of Gopakumar Menon as Chief Executive Officer to Lead the Global Clinical Research Organization
Date:3/7/2012

MUMBAI, India, March 7, 2012 /PRNewswire/ --

SIRO Clinpharm, a leading full service Clinical Research Organization announced the appointment of Gopakumar Menon as Chief Executive Officer. SIRO has developed a long term plan to align with the changing dynamics of the biopharma industry, and his primary charter is to transform SIRO into a global leader in the CRO and FSP space. He will be responsible for continuing to build and enhance the biopharma service catalog for SIRO's global delivery model, across the Americas, Europe and Asia.

"It is a pleasure to have Gopakumar on board. Gopakumar brings with him rich experience in driving business growth, and delivering tremendous value for leading companies, including Fortune 1000 companies," said Dr. Gautam Daftary, Chairman of SIRO Clinpharm. "Gopakumar has an excellent track record in cultivating partnership based relationships with Fortune 500 pharmaceutical client base, envisioning cutting-edge business and technical solutions for clients across U.S., Europe, Japan, India, China and Singapore. His experience and knowledge will help SIRO to enhance its services, and build a strong presence in new markets where the company plans to expand its frontiers."

"The biopharma industry is undergoing significant transformations. Clients are actively seeking quality service providers from the emerging markets, who can understand their specific challenges, and partner to build and deliver innovative solutions in a global delivery model," said Gopakumar. "My first priority will be to leverage decades of experience, tremendous value, and geographic reach of SIRO to make it the partner of choice for business critical services of global biopharma leaders. I look forward to working with Gautam and SIRO's board of directors."

Gopakumar has been with the pharmaceutical industry for the more than 12 years, where he worked in various capacities, from discovery to sales and marketing.

Prior to joining SIRO Clinpharm, Gopakumar was with Boston based Sciformix Inc. Gopakumar has had significant experience working with Fortune 500 companies like Cognizant and Satyam, in their Life Sciences divisions, as well as with venture funded start-up organizations.

About SIRO:

SIRO Clinpharm, winner of Frost & Sullivan Indian Clinical Research Organization of the year 2011 award, is a drug development solutions provider to the global healthcare industry. Our subject expertise gives us an edge in data management, medical writing, biostatistics & clinical trial management. Having a successful track record of 16 years, SIRO works with most top global biopharma & medical device companies. Our therapeutic experience includes but is not limited to oncology, diabetes, cardiology, infectious diseases & respiratory system. We offer flexible business models across service verticals based on client needs.

The company has offices in India, Malaysia, USA, and Israel and in Europe at Germany, Romania, Estonia, Greece, Czech Republic and Spain.

For more information please visit our website- http://www.siroclinpharm.com

Media contact:

Ruchi Sanganeria
Corporate Marketing
Tel: +91-22-2584-8000
ruchi.sanganeria@siroclinpharm.com


'/>"/>
SOURCE SIRO Clinpharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
2. SIRO Clinpharm and CambReg Ltd Strategic Alliance to Offer Regulatory Services in Europe
3. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
4. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
5. SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS
6. SIRO Clinpharms Nimita Limaye Elected as Chairperson of Society for Clinical Data Management (SCDM)
7. SIRO Clinpharm Expands Presence in Asia
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):